首页|基于肿瘤因子、炎症状态探究紫杉醇白蛋白辅助铂类化疗治疗复发转移性宫颈癌的疗效及安全性

基于肿瘤因子、炎症状态探究紫杉醇白蛋白辅助铂类化疗治疗复发转移性宫颈癌的疗效及安全性

扫码查看
目的:基于肿瘤因子、炎症状态探究紫杉醇白蛋白辅助铂类化疗治疗复发转移性宫颈癌的疗效及安全性。方法:选取2020年1月至2023年1月本院100例复发转移性宫颈癌患者,采用电脑随机数字表法随机分为两组,其中对照组50例,采用紫杉醇辅助奈达铂方案治疗,研究组50例,采用紫杉醇白蛋白辅助奈达铂方案治疗。比较两组近期疗效、肿瘤因子、炎症因子、复发转移相关指标、生存质量、功能状态、不良反应。结果:研究组总缓解率(72。00%)高于对照组(48。00%)(P<0。05);研究组治疗1个周期、3个周期后血清细胞角蛋白19片段抗原21-1(CYFRA21-1)、糖链抗原724(CA724)、鳞状细胞癌抗原(SCC-Ag)、白介素-4(IL-4)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平低于对照组,血清微小RNA-367(miR-367)、微小RNA-383(miR-383)水平、肿瘤患者生活质量评分(QOL)、卡氏功能状态评分(KPS)评分高于对照组(P<0。05);研究组治疗期间恶心/呕吐、腹泻、疲倦、白细胞减少、过敏反应发生率与对照组比较,差异无统计学意义(P>0。05),但总不良反应发生率(12。00%)低于对照组(32。00%)(P<0。05)。结论:紫杉醇白蛋白辅助奈达铂在复发转移性宫颈癌治疗中疗效可靠,能进一步下调肿瘤因子水平,缓解炎症状态,且安全性较高。
Efficacy and safety of paclitaxel albumin assisted platinum chemo-therapy in the treatment of recurrent and metastatic cervical cancer based on tumor factors and inflammatory status
AIM:To investigate the efficacy and safety of paclitaxel albumin assisted platinum che-motherapy in the treatment of recurrent and meta-static cervical cancer based on tumor factors and in-flammatory status.METHODS:A total of 100 pa-tients with recurrent and metastatic cervical cancer in our hospital from January 2020 to January 2023 were randomly divided into two groups:50 pa-tients in the control group were treated with pacli-taxel-assisted nedaplatin regimen,and 50 patients in the study group were treated with paclitaxel-as-sisted nedaplatin regimen.The short-term efficacy,tumor factors,inflammatory factors,relapse-metas-tasis related indexes,quality of life,functional sta-tus and adverse reactions were compared between the two groups.RESULTS:The total remission rate of the study group(72.00%)was higher than that of the control group(48.00%)(P<0.05).In the study group,after one and three cycles of treatment,se-rum cytokeratin 19 fragment antigen 21-1(CY-FRA21-1),carbohydrate antigen 724(CA724),squa-mous cell carcinoma antigen(SCC Ag),interleukin-4(IL-4),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)The levels of serum microrna-367(mir-367),microrna-383(mir-383),quality of life(QOL)and Karnofsky functional status score(KPS)in the tu-mor patients were significantly higher than those in the control group(P<0.05);There was no signifi-cant difference in the incidence of nausea/vomit-ing,diarrhea,fatigue,leukopenia and allergic reac-tions between the study group and the control group during treatment(P>0.05),but the total inci-dence of adverse reactions(12.00%)was lower than that of the control group(32.00%)(P<0.05).CONCLUSION:Paclitaxel albumin-assisted nedaplat-in has a reliable effect in the treatment of recurrent and metastatic cervical cancer,which can further reduce the level of tumor factors,relieve inflamma-tion,and has high safety.

recurrent metastatic cervical cancerpaclitaxel albuminnedaplatintumor factorin-flammatory state

周英、王立群

展开 >

蚌埠医学院第一附属医院,蚌埠 233004,安徽

复发转移性宫颈癌 紫杉醇白蛋白 奈达铂 肿瘤因子 炎症状态

2019年度蚌埠医学院科研项目

BYKY2019119ZD

2024

中国临床药理学与治疗学
中国药理学会

中国临床药理学与治疗学

CSTPCD北大核心
影响因子:0.97
ISSN:1009-2501
年,卷(期):2024.29(2)
  • 24